IL17A and neoplasm: Secretion of IL-17, G-CSF, IL-6 and SDF1in tumor microenvironment recruits CD11b+Gr1+ myeloid cells to tumor and conferring Bv8-associated VEGFR-independent angiogenesis leads to resistance to anti-VEGFR therapy.